50 completed, 12 unknown, 6 terminated, 4 recruiting. 17 Phase 4, 10 Phase 3, 9 Not applicable, 7 Phase 2, 3 Phase 1.
Follow Dipeptidyl-Peptidase IV Inhibitors: new trials by email Literature Review of Dipeptidyl-Peptidase IV Inhibitors trials Research Report on Dipeptidyl-Peptidase IV Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC Oxaliplatin, Capecitabine, Anti-PD-1 monoclonal antibody - Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 138 | 2026-04-09 | 2026-05-13 |
| Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm) - Breast Cancer | Phase 4 | Recruiting | Tanta University | 150 | 2026-02-01 | 2026-10-15 |
| Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus Semaglutide (1 Mg Dose), Sitagliptin (DPP4 inhibitor) - Type 2 Diabetes | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 240 | 2025-06-01 | 2026-01-28 |
| Antidiabetic Medications and Risk of Cancer Metformin, sulphonylurea, DPP-4 inhibitor - Cancer | Completed | University of Pecs | 74799 | 2025-03-15 | 2026-06-05 | |
| Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes SGLT2 inhibitor, Thiazolidinedione, DPP-4 inhibitor - Diabetes Mellitus, Type 2 | Recruiting | Chong Kun Dang Pharmaceutical | 10000 | 2024-01-02 | 2026-09-30 | |
| The Effects of DPPIs on Cognitive Function of Diabetic Patients Control group, DPP-4 inhibitor group, DPP-4 inhibitor + metformin group - Cognitive Impairment | Phase 4 | Unknown | Beni-Suef University | 105 | 2023-12-30 | 2023-12-11 |
| Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study. sulfonylurease with metformin, DPP4 inhibitors with Metformin - Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 200 | 2023-08-25 | 2024-08-26 | |
| Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database Dipeptidyl peptidase-4 inhibitor - Cerebral Infarction, Infarction, Brain | Unknown | Ajou University School of Medicine | 22119 | 2023-08-01 | 2023-07-20 | |
| Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System Dipeptidyl peptidase-4 inhibitors - Time in Range | Phase 3 | Completed | Ain Shams University | 50 | 2023-03-23 | 2023-09-01 |
| Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors Semaglutide, DPP-4 inhibitor - Diabetes | Completed | Brigham and Women's Hospital | 742670 | 2022-11-30 | 2025-11-10 | |
| Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes Dipeptidyl peptidase 4 (DPP-4) inhibitor - Diabetes Mellitus, Type 1, NASH | Phase 3 | Completed | Ain Shams University | 60 | 2022-11-10 | 2024-04-05 |
| Therapeutic Drug Use for CKD Patients angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker - Chronic Kidney Disease | Unknown | Qianfoshan Hospital | 10000 | 2022-07-01 | 2024-04-03 | |
| The Effect of Semaglutide on Cardiovascular Markers and Liver Function Semaglutide, 1.0 mg/mL, Dipeptidyl Peptidase 4 inhibitor - Diabetes Type 2 | Unknown | Attikon Hospital | 50 | 2022-03-01 | 2024-03-08 | |
| Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting), gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed) - Healthy Volunteers | Phase 1 | Unknown | LG Chem | 28 | 2022-01-01 | 2021-11-03 |
| Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor - Type 2 Diabetes, Cardiac Disease | Completed | Mayo Clinic | 386301 | 2021-12-01 | 2025-10-10 | |
| ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT Biguanide, DPP4 inhibitors, SGLT2 inhibitors - Abdominal Obesity, Type 2 Diabetes | Not applicable | Unknown | Metabolic Research Unit | 30 | 2021-08-01 | 2021-09-09 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients? Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG - Diabete Type 2 | Not applicable | Completed | Sadat City University | 175 | 2020-09-20 | 2022-05-03 |
| Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus Dipeptidyl-Peptidase IV Inhibitors - PreDiabetes, Type 2 Diabetes | Phase 3 | Completed | National University of Malaysia | 50 | 2020-08-01 | 2022-03-22 |
| Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) Canagliflozin, DPP4 inhibitor, Liraglutide - Type 2 Diabetes Mellitus | Completed | AstraZeneca | 239990 | 2020-05-15 | 2024-08-30 |
Showing 20 of 77. Sign in to see all of them.
Diabetes Mellitus, Type 2 (47) · Diabetes Mellitus (19) · Diabetes Mellitus, Type 1 (5) · Heart Failure (3) · Diabetic Nephropathies (2) · Hyperglycemia (2) · Renal Insufficiency, Chronic (2) · Albuminuria (1) · Alzheimer Disease (1) · Brain Infarction (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Cerebral Infarction (1) · Cognitive Dysfunction (1) · Colorectal Neoplasms (1)
Brigham and Women's Hospital (7) · Boehringer Ingelheim (4) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Novo Nordisk A/S (3) · University of British Columbia (3) · Ain Shams University (2) · Attikon Hospital (2) · Hoffmann-La Roche (2) · Royal Devon and Exeter NHS Foundation Trust (2) · University of Sao Paulo General Hospital (2) · Ajou University School of Medicine (1) · Assistance Publique Hopitaux De Marseille (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)
United States (21) · Canada (9) · China (5) · Egypt (5) · South Korea (5) · United Kingdom (5) · Brazil (3) · Greece (3) · Italy (3) · Poland (3) · Puerto Rico (3) · Bulgaria (2) · Czechia (2) · Denmark (2) · Hungary (2)
Shirley Wang, PhD, ScM (4) · Pierre Ernst, MD, MSc (3) · Andrew T Hattersley, FRCP, DM, BM (2) · Graydon Meneilly, MD (2) · Alexey Medvedchikov, +43180105-7896 (1) · Alvin Mushlin (1) · Anton Cheng, MBBS (1) · Bernardo L Wajchenberg, PhD (1) · Bonnie Spring, PhD (1) · Carel W le Roux, PhD MB FRCP (1) · Cristina S Oliveira, Pos Grad (1)
PMID 33327727, PMID 39963952, PMID 16732016, PMID 17098089, PMID 17622601, PMID 21668924, PMID 23209191, PMID 23490599, PMID 23524641, PMID 23645885, PMID 23690531, PMID 24516103, PMID 25158865, PMID 26888382, PMID 27007958, PMID 27281773, PMID 27314342, PMID 27479930, PMID 28083033, PMID 28213915, PMID 28228317, PMID 28405346, PMID 29310645, PMID 29322610, PMID 29507862, PMID 29748996, PMID 29907893, PMID 30558400, PMID 30794833, PMID 30954510, PMID 30955357, PMID 31074791, PMID 31284526, PMID 31334795, PMID 31368793, PMID 31391203, PMID 31393176, PMID 31604171, PMID 32027799, PMID 32139384, PMID 32168769, PMID 32450102, PMID 32827752, PMID 32960514, PMID 32998054, PMID 32998732, PMID 33288412, PMID 33334808, PMID 33502058, PMID 33737203
2015 (1), 2018 (1), U01DK098246 (1)